Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1123
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-01-28
ImmuneCare, a Subsidiary of ImmuneOnco, Files Patent for IMC-015 Bispecific Antibody Differentiated "Fat-Loss & Muscle-Gain" Strategy Poised to Tackle GLP-1-Induced Muscle Loss
More
2026-01-21
ImmuneOnco Presents at J.P. Morgan Healthcare Conference: Biotech Showcase™ Presentation Highlights Progress of Core Programs Including IMM01
More
2026-01-19
ImmuneCare, a Subsidiary of ImmuneOnco, Successfully Completes Subject Enrollment for First Cohort in MAD Study of IMC-003 for Pulmonary Arterial Hypertension
More

For more information

Please follow the official wechat public account